Acurx Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
Acurx Pharmaceuticals, Inc. filed a Form 8-K reporting the results of its annual meeting of stockholders held on June 7, 2022. The company is incorporated in Delaware, trades under the symbol ACXP on Nasdaq, and reported 5,689,473 shares represented at the meeting, equal to approximately 55.43% of outstanding common stock. A quorum was present.
Financial and operating metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance information.
Material changes versus the prior comparable period
The filing reports voting outcomes only and does not disclose a comparable-period financial update or other material operating change.
Meeting results, outlook, and risks
- Director elections: Carl V. Sailer and Thomas Harrison were elected as Class I directors to serve until the 2025 annual meeting.
- Carl V. Sailer received 3,743,543 votes for, 289,750 withheld, and 1,656,180 broker non-votes.
- Thomas Harrison received 3,741,578 votes for, 291,715 withheld, and 1,656,180 broker non-votes.
- Auditor ratification: Stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- The auditor proposal received 5,584,342 votes for, 98,801 against, and 6,330 abstentions; there were no broker non-votes.
- The filing provides no new management guidance, financial outlook, contingencies, or risk disclosures.
Important facts for investors to verify
- Confirm the elected directors’ appointments and terms through subsequent company filings.
- Review later filings for the company’s fiscal-year 2022 financial condition, cash runway, financing needs, and auditor reports.
- Assess the implications of the 55.43% meeting representation and the number of broker non-votes in director elections.
- Verify whether any subsequent filing reports changes in governance, auditor status, or corporate strategy.